Ajay Nyamati’s Post

🧬 𝐅𝐚𝐜𝐢𝐧𝐠 𝐛𝐨𝐭𝐭𝐥𝐞𝐧𝐞𝐜𝐤𝐬 𝐨𝐟 𝐂𝐀𝐑-𝐓 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 Since the first approval of CAR-T in 2017, six products have made it to the U.S. market to treat various blood cancers. Despite their great efficacy and rapid growth trajectory, CAR-T therapies still face several challenges: ⚆ Healthcare infrastructure - Hospitals face significant challenges in expanding their infrastructure to accommodate the complex needs of CAR-T therapy patients and to address side effects ⚆ Human resources - Delivering CAR-T to patients requires a specialized, multidisciplinary team of healthcare professionals, which is challenging due to shortages (especially of nurses) and overall burnout within the sector ⚆ Financial and operational efficiency - Money, money, money. Let's not forget about the costs of CAR-T. These treatments are expensive and complex to manufacture, which makes it difficult to plan and efficiently deliver CAR-T to patients 𝘏𝘰𝘸 𝘤𝘢𝘯 𝘵𝘩𝘦𝘴𝘦 𝘭𝘪𝘮𝘪𝘵𝘢𝘵𝘪𝘰𝘯𝘴 𝘣𝘦 𝘰𝘷𝘦𝘳𝘤𝘰𝘮𝘦? More info: https://lnkd.in/dzhwdRdr #cart #celltherapy #oncology #pharma #drugdiscovery #innovation #drjojo

https://lnkd.in/g3BAYM8d Excited to co-author and partner with Brian Williams to bring forward a white paper "Connect Clinical Innovation with Commercial Success". Integrating digital assets into new biopharmaceutical commercial models can bolster patient support and deepen clinician engagement while providing demonstrable health outcomes. We explore how clinical advances in Multiple Myeloma can be paired with digital tools as an example for Life Sciences companies. CAR-T is an area of opportunity to bring greater innovation for patients, caretakers and healthcare teams.

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP